Robert Shellman, MD
Pulmonary Disease · Shelbyville, INNPI 1659339927
Payments from drug & device makers
Across 795 payments — averaging $20.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- GSK$2K
- Regeneron Healthcare Solutions, Inc.$872
- Boehringer Ingelheim$807
- Harmony Biosciences LLC$793
- Sanofi$780
- plus $7K from 42 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$16,158 in reported general payments places this provider in the 80th percentile of 258 pulmonary disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Shelbyville
- Cynthia BrownIndianapolis$7.3M
- Imad ShawaGreenwood$1.4M
- David MaresAnderson$1.3M
- Raja DevanathanHobart$862K
- Olusegun ApataGary$780K
- David WilsonSeymour$689K
- Giovanni InfusinoCrown Point$526K
- Faisal KhanGreenwood$400K
- Sandeep KukrejaGreenwood$375K
- Ajay DeshpandeTerre Haute$304K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.